These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8081030)

  • 21. [Role of bisphosphonates in the treatment of tumoral osteolysis].
    Claudepierre P; Puéchal X; Menkès CJ
    Ann Med Interne (Paris); 1995; 146(5):325-7. PubMed ID: 8526319
    [No Abstract]   [Full Text] [Related]  

  • 22. [The effect of clodronate on bone density in patients with multiple myeloma--a 2-year follow-up of therapeutic effects].
    Adam Z; Prokes B; Znojĭl V; Vorlícek J; Hejlová N; Hájek D; Krejcí M
    Vnitr Lek; 1996 Jun; 42(6):379-85. PubMed ID: 8928406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
    Delibasi T; Altundag K; Kanlioglu Y
    J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
    [No Abstract]   [Full Text] [Related]  

  • 24. Intravenous pamidronic acid: new indications. Useful palliative treatment for osteolysis.
    Prescrire Int; 1998 Aug; 7(36):103-5. PubMed ID: 10342945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma.
    Delmas PD; Charhon S; Chapuy MC; Vignon E; Briancon D; Edouard C; Meunier PJ
    Metab Bone Dis Relat Res; 1982; 4(3):163-8. PubMed ID: 6218370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aredia: the once-monthly infusion for the treatment of bone metastases.
    Lipton A
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients--the American experience.
    Berenson J
    Br J Clin Pract Suppl; 1996 Sep; 87():5-7; discussion 13-4. PubMed ID: 8995010
    [No Abstract]   [Full Text] [Related]  

  • 30. [Biphosphonates in the treatment of bone metastasis of prostatic cancer].
    Paule B; Cicco A
    Prog Urol; 2001 Dec; 11(6):1205-12. PubMed ID: 11859653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clodronate and myeloma].
    Jantunen E; Lahtinen R; Laakso M
    Duodecim; 1995; 111(12):1085-7. PubMed ID: 9213542
    [No Abstract]   [Full Text] [Related]  

  • 32. [Biphosphonates as a treatment for arresting metastasis. A new indication?].
    Azuri J; Halabe A
    Harefuah; 1998 Dec; 135(11):522-4. PubMed ID: 10911470
    [No Abstract]   [Full Text] [Related]  

  • 33. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
    Body JJ
    Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biphosphonates and prostatic cancer. A survey of a Cochrane review].
    Jønler M; Borre M
    Ugeskr Laeger; 2007 Nov; 169(47):4058-61. PubMed ID: 18078660
    [No Abstract]   [Full Text] [Related]  

  • 35. [Biphosphonates in breast cancer--based on a Cochrane meta-analysis].
    Junker N; Nielsen DL; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3108-11. PubMed ID: 17877961
    [No Abstract]   [Full Text] [Related]  

  • 36. A time for perspective on bisphosphonates.
    Assael LA
    J Oral Maxillofac Surg; 2006 Jun; 64(6):877-9. PubMed ID: 16713799
    [No Abstract]   [Full Text] [Related]  

  • 37. How can we improve the treatment of bone metastases further?
    Coleman RE
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S7-13. PubMed ID: 9801853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases.
    de Vernejoul MC
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):119S-123S. PubMed ID: 9273953
    [No Abstract]   [Full Text] [Related]  

  • 39. The cyclic use of multiple alkylating agents in multiple myeloma.
    Harley JB; Ramanan SV; Kim I; Thiagarajan PV; Chen JH; Gomez R; Koppel D; Hyde F; Gustke S; Krall J
    W V Med J; 1972 Jan; 68(1):1-3. PubMed ID: 4500402
    [No Abstract]   [Full Text] [Related]  

  • 40. Skeletal Complications of Malignancy. Proceedings of a symposium. Bethesda, Maryland, April 19-20, 1997.
    Cancer; 1997 Oct; 80(8 Suppl):1527-701. PubMed ID: 9377495
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.